# OnCo record rivoceranib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rivoceranib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rivoceranib" ;
  schema:name "Rivoceranib (apatinib)"@en ;
  schema:alternateName "Apatinib"@en, "Aitan" ;
  schema:description "Apatinib, sold as rivoceranib outside China, was the first pill of its kind approved for stomach cancer and is now the partner of camrelizumab in first-line liver cancer."@en ;
  schema:url <https://onco.cc/drugs/rivoceranib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Apatinib> ;
  schema:citation <https://www.hengrui.com/en/>, <https://doi.org/10.1016/S0140-6736(23)00961-3>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule VEGFR2 TKI" ;
  onco:approval "China 2014: Advanced gastric or gastro-oesophageal junction adenocarcinoma after two or more lines", "China 2020: Advanced hepatocellular carcinoma after prior systemic therapy", "China 2023: First-line unresectable hepatocellular carcinoma with camrelizumab (CARES-310)" ;
  onco:related <https://onco.cc/drugs/camrelizumab-rivoceranib/>, <https://onco.cc/drugs/camrelizumab/> ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/hcc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:pathways <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:trials <https://onco.cc/trials/cares-310/>, <https://onco.cc/trials/nct04639180/>, <https://onco.cc/trials/nct05320692/>, <https://onco.cc/trials/nct05934331/>, <https://onco.cc/trials/nct04342910/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-qin-lancet/> .